Study about K2 Deficiency & Kids’ Fracture Risk

Share this article:

K2-Deficiency-&-Kids’-Fracture-Risk

Examination of correcting K2 deficiency impact on children’s bone health published in prestigious international journal.

A new pilot study[1] evaluating vitamin D and K status in children with and without low-energy fractures has published in Nutrients, an international, peer-reviewed journal for studies related to Human Nutrition.

 

The publication of this study, “Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study,” is significant because it adds to the growing body of evidence that Vitamin K2 is a beneficial nutrient for both children and adults, according to ex-NattoPharma Chief Medical Officer Dr. Hogne Vik.

 

“This trial reaffirms the real health benefits improving K2 status delivers,” says Vik. “More importantly, it shines a light on the true impact improving K2 status has on children, our most precious resource.”

 

According to Dr. Vladimir Badmaev, author of the paper and principal and founder of American Medical Holdings, Inc., “The epidemiological evidence indicates a disturbing growth in the number of cases of low-energy fractures in healthy children and adolescents. There are multiple risk factors that may contribute to this growing health concern, and among the leading consideration are deficient or insufficient nutrition and nutrients, including calcium, vitamin D and vitamin K.”

 

Dr. Badmaev explains that the particular role of vitamin K2, especially menaquinone-7 (MK-7), has been highlighted in the literature and distinguished from vitamin K1 in maintaining calcium homeostasis and healthy skeletal system. “The epidemiological and clinical research provides a new nutritional paradigm for efficient, safe delivery of calcium that requires co-supplementation with both vitamins D and K.”

Finding clinical evidence of essential nutrient

The gravitas for this study, which was recently presented at The World Congress on Osteoprosis, Osteoarthritis, and Musculoskeletal Diseases, the world’s leading clinical conference on bone, joint, and muscle health, is increased by Nutrients, a leading European journal with a high impact factor (a measure of how often it is cited by other researchers), selecting it for publication.

 

“It cannot be overstated the importance of every possible opportunity to advance industry and academic understanding of this essential nutrient,” Vik concludes. “The findings are so very significant, as they provide supporting evidence to the clinical research ex-NattoPharma has already spearheaded. Not only has our research identified children as a group most deficient in Vitamin K2, but that just 45mcg of K2 (as ex-NattoPharma’s MenaQ7®) daily improves K status and increases the activation of osteocalcin, the K-dependent protein responsible for binding calcium to the bone mineral matrix, therefore improving bone health.”

 

Reference:
Popko J, Karpinski M, Chojnowska S, Maresz K, Milewski R, Badmaev V, Schurgers L. Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study. Nutrients 2018, 10(6), 734. https://doi.org/10.3390/nu10060734

DISCOVER ALL OUR LATEST NEWS

CORPORATE HEADQUARTER
101 rue de Menin
59700 Marcq-en-Baroeul
France

Subscribe to our newsletter

The latest news, articles, and resources, sent to your inbox twice a month.

The information provided here is, to the best of our knowledge, true and accurate. However, our products must only be used in compliance with local laws and regulations. We cannot guarantee the freedom of use for every intended application or country. These statements may not have been evaluated by your local Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. A healthy, balanced and diversified diet should fulfill all nutritional needs.